Maximizing Analgesia to Reduce Pain in Knee Osteoarthritis
CompletedPhase 2NCT03098563
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
This research is being done to evaluate whether combining medications that are FDA approved, but have not yet been approved for combination treatment, can be effective in reducing pain.
Study details
- Official title
- Maximizing Analgesia to Reduce Pain Sensitivity in Chronic Knee Osteoarthritis Pain Patients
- Conditions
- Interventions
- Drug: Blinded study medication
- Sponsor
- Johns Hopkins University
- Collaborators
- National Institute on Drug Abuse (NIDA)
- Start date
- 2017-11-01
- Primary completion
- 2023-11-17
- Sex
- All
- Age range
- from 45 Years
- Results posted
- Yes, on ClinicalTrials.gov
- Countries
- United States
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Diagnosis of knee osteoarthritis * Urine sample tests negative for common illicit substances of abuse (e.g., cannabis) * Medically cleared to take study medications * Are not pregnant or breast feeding * Willing to comply with the study protocol. Exclusion Criteria: * Pain other than Knee Osteoarthritis * Taking opioids for pain * Prescribed and taking gabapentinoid, Tricyclic Antidepressants (TCA), venlafaxine, duloxetine, stimulants or benzodiazepines * Presence of any clinically significant medical/psychiatric illness judged by the investigators to put subject at elevated risk for experiencing an adverse event * Known allergy to the blinded study medications
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT03098563